Evaluation of Antiproliferative Effects of Arimidex in Ductal Lavage Fluid in Patients With Breast Cancer
|ClinicalTrials.gov Identifier: NCT01207635|
Recruitment Status : Completed
First Posted : September 23, 2010
Last Update Posted : July 30, 2012
The goal of this study is to evaluate antiproliferative effects of Arimidex in ductal lavage fluids of Breast Cancer patients.
Breast cancer is the leading cause of cancer incidence and the second leading cause of cancer mortality in women. Breast duct fluid provide biomarkers to aid in risk assessment of developing breast cancer.
|Condition or disease||Intervention/treatment|
|Breast Cancer||Procedure: Ductal Lavage Fluid Collection|
|Study Type :||Observational|
|Actual Enrollment :||42 participants|
|Official Title:||Evaluation of Antiproliferative Effects of Arimidex in Ductal Lavage Fluid in Patients With Breast Cancer|
|Study Start Date :||November 2002|
|Actual Primary Completion Date :||January 2006|
|Actual Study Completion Date :||January 2006|
|Breast Cancer Patients||
Procedure: Ductal Lavage Fluid Collection
Procedure of inserting a small catheter into the ductal openings in the nipple and washing out cells from inside the duct.
- Number of Patients with Antiproliferative Effects of Arimidex [ Time Frame: Study duration 4 years ]Biomarker modulation study on effects of Armimidex in ductal lavage fluid from evaluable epithelial cells specimen.
Biospecimen Retention: None Retained
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01207635
|United States, Texas|
|UT MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Study Chair:||Banu Arun, MD||UT MD Anderson Cancer Center|